EGFR and tongue squamous cell carcinoma: Gefitinib, a selective tyrosine kinase inhibitor of EGFR, induced a reduction in OCT4 and SOX2 levels in CAL‐27 and SCC‐15 cells, two human tongue squamous cell carcinoma cell lines.